A detailed history of Jane Street Group, LLC transactions in Savara Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 64,919 shares of SVRA stock, worth $214,881. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,919
Previous 88,566 26.7%
Holding current value
$214,881
Previous $356,000 22.75%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.96 - $5.07 $93,642 - $119,890
-23,647 Reduced 26.7%
64,919 $275,000
Q2 2024

Aug 14, 2024

BUY
$3.66 - $5.34 $9,944 - $14,508
2,717 Added 3.16%
88,566 $356,000
Q1 2024

May 15, 2024

BUY
$4.19 - $5.59 $106,388 - $141,935
25,391 Added 42.0%
85,849 $427,000
Q4 2023

Feb 14, 2024

BUY
$3.18 - $4.9 $192,256 - $296,244
60,458 New
60,458 $284,000
Q2 2023

Aug 14, 2023

SELL
$1.69 - $3.24 $326,475 - $625,906
-193,181 Reduced 68.42%
89,164 $284,000
Q1 2023

May 15, 2023

BUY
$1.6 - $2.82 $418,540 - $737,678
261,588 Added 1260.24%
282,345 $550,000
Q4 2022

Feb 14, 2023

BUY
$1.11 - $1.64 $4,158 - $6,143
3,746 Added 22.02%
20,757 $32,000
Q3 2022

Nov 14, 2022

BUY
$1.36 - $1.88 $23,134 - $31,980
17,011 New
17,011 $26,000
Q3 2021

Nov 16, 2021

SELL
$1.18 - $1.64 $24,578 - $34,159
-20,829 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$1.51 - $2.29 $31,451 - $47,698
20,829 New
20,829 $35,000
Q4 2020

Feb 17, 2021

SELL
$1.0 - $1.47 $14,346 - $21,088
-14,346 Closed
0 $0
Q3 2020

Nov 17, 2020

SELL
$1.09 - $2.21 $3,123 - $6,333
-2,866 Reduced 16.65%
14,346 $16,000
Q2 2020

Aug 17, 2020

BUY
$1.8 - $3.05 $30,981 - $52,496
17,212 New
17,212 $43,000
Q1 2020

May 15, 2020

SELL
$1.91 - $4.08 $20,878 - $44,598
-10,931 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$0.71 - $4.91 $7,761 - $53,671
10,931 New
10,931 $49,000
Q1 2019

May 16, 2019

SELL
$6.71 - $8.6 $82,190 - $105,341
-12,249 Closed
0 $0
Q4 2018

Feb 15, 2019

BUY
$6.27 - $10.92 $76,801 - $133,759
12,249 New
12,249 $93,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $377M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.